NeoPhore
PrivateLast Round
Series B
Extension
May 22, 2024
Total Funding Raised
$68.42M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NeoPhore operates in Healthcare & Life Sciences and is based in Altrincham. Its latest recorded funding round was a Series B Extension round in May 2024.
NeoPhore is a biotechnology company that develops small molecule immuno-oncology therapies targeting the DNA mismatch repair pathway to stimulate the immune system against cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeoPhore Comparables
Compare NeoPhore with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Grey Wolf Therapeutics | 78% | |
| Artios Pharma | 75% | |
| FoRx Therapeutics | 75% |
For institutional investors. Book with your work email.
NeoPhore Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 22, 2024 | ||||
| Series B Extension | Jan 19, 2023 | ||||
| Series B | Mar 9, 2021 | ||||
| Grant | Apr 27, 2018 | ||||
| Seed | Nov 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeoPhore Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 3B FUTURE Health Fund | Series B, Series B Extension |
| Neva SGR | Series B, Series B Extension |
| Sixth Element Capital | Seed |
| Claris Ventures | Series B Extension, Series B |
| 2invest AG | Series B, Series B Extension |
| Simon Fiduciaria | Series B, Series B Extension |
| Astellas Venture Management | Series B, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 81% MoM.
- Jul 26, 2026
Monthly visitors grew 325% MoM.
For institutional investors. Book with your work email.
NeoPhore Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeoPhore's valuation, stock price, and market status.
Is NeoPhore a public or private company?
NeoPhore is a private company.
What is the current stock price of NeoPhore?
NeoPhore is a private company, so its shares have no public market price. Caplight tracks NeoPhore's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeoPhore worth (valuation)?
Valuation information for NeoPhore is not publicly available.
Can I buy NeoPhore stock?
NeoPhore shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeoPhore's last funding round?
NeoPhore's most recent funding round was Series B Extension on May 22, 2024.
Who are the main investors in NeoPhore?
Key investors in NeoPhore include Sixth Element Capital, Claris Ventures.
Will NeoPhore IPO soon?
No public IPO plans have been announced for NeoPhore.
How can I track NeoPhore secondary market activity?
Caplight tracks bids, offers, and trades in NeoPhore's shares on secondary markets.